This page shows the latest UniQure news and features for those working in and with pharma, biotech and healthcare.
In a statement, uniQure said that the patient diagnosed with HCC had ‘multiple risk factors’ associated with this type of cancer. ... UniQure added that all patients in its haemophilia clinical programme have abdominal ultrasounds performed one year
Athough, analysts at Jefferies have previously suggested that with a number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
number of other companies developing gene therapies – including BioMarin, Sangamo and UniQure – that should not be considered overly dominant.
Analysts at Jefferies have suggested that is unlikely to be the case, given that a number of other companies are developing haemophilia gene therapies including BioMarin, Sangamo and UniQure which all
BioMarin’s ValRox, which is expected to launch as early as 2020, and Spark Therapeutics’ SPK-8011 for haemophilia A, and uniQure’s AMT-061 and Pfizer/Spark Therapeutics’ SPK-9001
Encouraging results for firms in four-way race. Sangamo and UniQure have continued to build the case for their one-shot gene therapies for haemophilia A and B, with new data ... uniQure thinks spontaneous bleeds decrease substantially when FIX activity
More from news
Approximately 13 fully matching, plus 22 partially matching documents found.
Gene therapy failures. The industry and Europe’s healthcare systems are wary of that magic one million threshold, thanks to the failure of the first ever gene therapy, UniQure’s Glybera. ... The success or failure of Bluebird will be closely watched
success. Europe has already seen two gene therapies approved but fail commercially – UniQure’s Glybera and GSK’s Strimvelis – and so Bluebird has to learn lessons on pricing and reimbursement and ... The EMA approved the world’s first ever
Unfortunate message. Some of these thorny problems were encapsulated in uniQure’s recent decision not to seek an extension to its five-year European marketing authorisation - which expires in October - for
BMS will also take a 4.9% equity stake in uniQure which will cost around $32m, with another 5% ownership scheduled before the end of the year (at 10% premium). ... UniQure also stands to receive research, development and regulatory milestones, including
32, 700. uniQure NV/ Bristol-Myers Squibb. R&D collaboration plus equity investment.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Meyer joins the biotech from uniQure B.V where he was chief medical officer and has held several similar roles for Cardoz, Symphogen, Zymenex and Novo Nordisk.
Based in the Netherlands and the US, uniQure has appointed Matthew Kapusta as its chief executive officer. ... This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals.
Will serve as gene therapy specialist's chief commercial officer. Gene therapy company uniQure has appointed Hans Christian Rohde to serve as its new chief commercial officer. ... In his new role at Netherlands-based uniQure he will be tasked with
More from appointments
Approximately 2 fully matching, plus 1 partially matching documents found.
There has already been one notable disappointment. In 2017 uniQure pulled its gene therapy, Glybera (alipogene tiparvovec) for the rare inherited disorder lipoprotein lipase deficiency (LPLD) from Europe after 5 years,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...